Accord Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACCORD, and what generic alternatives to ACCORD drugs are available?
ACCORD has one hundred and fifty-five approved drugs.
There are four US patents protecting ACCORD drugs. There are three tentative approvals on ACCORD drugs.
There are thirty-five patent family members on ACCORD drugs in eighteen countries and three hundred and eighty-six supplementary protection certificates in eighteen countries.
Summary for Accord
| International Patents: | 35 |
| US Patents: | 4 |
| Tradenames: | 132 |
| Ingredients: | 129 |
| NDAs: | 155 |
| Patent Litigation for Accord: | See patent lawsuits for Accord |
| PTAB Cases with Accord as petitioner: | See PTAB cases with Accord as petitioner |
Drugs and US Patents for Accord
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | DIMETHYL FUMARATE | dimethyl fumarate | CAPSULE, DELAYED RELEASE;ORAL | 210499-002 | Sep 24, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Accord Hlthcare | METHOTREXATE SODIUM | methotrexate sodium | TABLET;ORAL | 213343-001 | Jan 24, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Accord Hlthcare | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 207477-001 | Jan 4, 2022 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Accord Hlthcare | ARIPIPRAZOLE | aripiprazole | TABLET;ORAL | 206251-006 | Dec 7, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ACCORD drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
International Patents for Accord Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3727421 | ⤷ Try a Trial |
| Russian Federation | 2756514 | ⤷ Try a Trial |
| Israel | 275448 | ⤷ Try a Trial |
| Japan | 2009523798 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Accord Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0817775 | SPC/GB06/008 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919 |
| 1746976 | 300885 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: IRINOTECANSUCROSOFAATZOUT; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
| 1381356 | SPC/GB14/011 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TERIFLUNOMIDE, ITS STEREOISOMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/838/001-005 20130829 |
| 1381356 | 14C0010 | France | ⤷ Try a Trial | PRODUCT NAME: TERIFLUNOMIDE,SON STEREOISOMERE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES.; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
